Preoperative evaluation of the patient with cardiac disease for noncardiac operations

Published on 07/02/2015 by admin

Filed under Anesthesiology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1183 times

Preoperative evaluation of the patient with cardiac disease for noncardiac operations

Harish Ramakrishna, MD, FASE

Cardiovascular disease is one of the leading causes of death worldwide and the chief cause of death in the United States. Cardiac complications following noncardiac operations account for the majority of the morbidity and mortality risks in the perioperative period, with incidences ranging from 1.5% in the unselected population to 4% in patients at risk for, or with cardiovascular disease, to as high as 11% in patients with multiple risk factors. The key role of the anesthesiologist as perioperative physician when confronted with the patient with cardiovascular disease for a noncardiac operation is to effectively identify patients with modifiable conditions and those at risk for experiencing cardiac events in the perioperative period. The risk stratification that follows is the basis for safe perioperative management of patients with cardiovascular disease. The key issues that need to be addressed are based on the American College of Cardiology/American Heart Association (ACC/AHA) Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. The revised guidelines also include recommendations for the management of patients with coronary artery stents and the perioperative use of β-adrenergic receptor blocking agents.

Defining comorbid conditions

The clinician needs to identify any active cardiac conditions (Table 106-1) or clinical risk factors that have been associated with adverse outcomes. Active cardiac conditions are defined as unstable coronary syndromes, decompensated systolic or diastolic heart failure, significant arrhythmias, and severe valvular heart disease. Clinical risk factors are independent risk factors that are associated with poor outcomes and include history of ischemic heart disease (suggestive history, symptoms, or Q waves on electrocardiogram), history of prior or compensated heart failure (suggestive history, symptoms, or examination findings), history of stroke or transient ischemic attack, insulin-dependent diabetes mellitus, and renal insufficiency (serum creatinine concentration >2 mg/dL).

Table 106-1

Active Cardiac Conditions That Mandate Preoperative* Evaluation and Treatment

Condition Examples
Unstable coronary syndromes Unstable or severe angina (CCS class III or IV)
Recent MI§
Decompensated HF (NYHA functional class IV; worsening or new-onset HF)  
Significant arrhythmias High-grade AV block
Mobitz type II AV block
Third-degree AV block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias, including AF, with uncontrolled ventricular rate (HR >100 beats/min at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
Severe valvular disease Severe aortic stenosis (mean pressure gradient >40 mm Hg, aortic valve area <1.0 cm2, or symptomatic
Symptomatic mitral stenosis (progressive dyspnea on exertion, exertional presyncope, or HF)

AF, Atrial fibrillation; AV, atrioventricular; CCS, Canadian Cardiovascular Society; HF, heart failure; HR, heart rate; NYHA, New York Heart Association.

*Before noncardiac operations.

According to Campeau L. Letter: Grading of angina pectoris. Circulation. 1976;54:522-523.

May include “stable” angina in patients who are sedentary.

§The American College of Cardiology (ACC) National Database Library defines “recent” myocardial infarction (MI) as occurring >7 days but ≤30 days previously.

Reprinted, with permission, from Fleisher L, Beckman J, Brown K, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;50:e159-241.

Assessing surgical risk

Evaluation of surgical risk is crucial. Surgical procedures have been classified as low-risk, intermediate-risk, and high-risk vascular operations (Table 106-2). Understandably, procedures with differing levels of stress (alterations in heart rate, blood pressure, intravascular volume, blood loss, and pain) are associated with differing levels of morbidity and mortality risks. Ophthalmologic and superficial procedures represent the lowest risk and very rarely result in morbidity and death. The intermediate-risk category (includes endovascular abdominal aortic aneurysm repair and carotid endarterectomy) represents procedures with associated morbidity and mortality risks that vary depending upon the surgical location and extent of procedure. Major vascular procedures are the highest risk procedures and mandate further investigation. In the revised ACC/AHA guidelines, vascular surgery is now the only surgical category listed as high risk or generally associated with a greater than 5% risk of perioperative cardiac complications.

Table 106-2

Surgical Risk* Stratification for Patients with Preexisting Cardiac Disease

Level of Risk Procedure Examples
High (vascular procedures) Aortic and other vascular operations
Peripheral vascular operations
Intermediate Intraperitoneal and intrathoracic operations
Carotid endarterectomy
Head and neck operation
Orthopedic operations
Prostate operations
Low§ Endoscopic procedures
Superficial procedures
Cataract operations
Breast operations
Ambulatory operations

*Combined incidence of cardiac death and nonfatal myocardial infarction.

Reported cardiac risk often >5%.

Reported cardiac risk generally 1%-5%.

§Reported cardiac risk generally <1%. These procedures do not generally require further preoperative cardiac testing.

Evaluating functional status

Assessment of functional status in the patient with cardiovascular and pulmonary disease is critical, because O2 uptake is considered to be the best measure of cardiovascular reserve and exercise capacity. Functional status is measured using metabolic equivalents (METS) (Table 106-3). One MET represents the O2 consumption of a person at rest (3-5 mL·kg−1·min−1). A functional capacity of 4 METs is considered the minimum requirement for a patient undergoing a major surgical procedure. Consequently, patients who are unable to meet a minimum 4-MET demand during daily activities are at higher risk for developing perioperative cardiovascular and pulmonary complications. Those patients with multiple medical comorbid conditions that limit activity will need to be formally tested to objectively determine cardiopulmonary reserve.

Table 106-3

Energy Requirement for Various Activities

Energy Expenditure Can You . . .
1 MET
Take care of yourself?
Eat, dress, or use the toilet?
Walk indoors around the house?
Walk a block or two on level ground at 2 to 3 mph (3.2 to 4.8 kph)?
4 METs
Do light work around the house, like dusting or doing dishes?
Climb a flight of stairs or walk up a hill?
Walk on level ground at 4 mph (6.4 kph)?
Run a short distance?
Do heavy work around the house, like scrubbing floors or lifting or moving heavy furniture?
>10 METs Participate in moderate recreational activities, like golf, bowling, dancing, doubles tennis, or throwing a football or baseball?

kph, Kilometers per hour; MET, metabolic equivalent; mph, miles per hour.

Reprinted, with permission, from Fleisher L, Beckman J, Brown K, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;50:e159-241.

Applying the revised american college of cardiology/american heart association guidelines

Once the clinician has performed a history and examination, the new 5-step ACC/AHA approach can then be utilized for risk stratification and determination of the need for additional cardiac testing (Figure 106-1).

Step 1. Is the noncardiac operation emergent? If so, the patient is taken to the operating room without delay, with the focus being appropriate intraoperative and postoperative cardiac surveillance.

Step 2. Is an active cardiac condition identified? If so, this mandates cardiology consultation and further diagnostic testing.

Step 3. Is the operation low risk? Recognizing that the risk for perioperative cardiac complications in low-risk operations is less than 1% even in high-risk patients, the guidelines state that the patient may proceed to surgery without further testing.

Step 4. If the patient demonstrates good functional capacity (being able to perform >4 METS of activity without cardiopulmonary symptoms) the patient may proceed to surgery.

Step 5. Patients with poor or indeterminate functional capacity for intermediate-risk or high-risk procedures must undergo an additional evaluation. The key issue here is the number of clinical predictors (derived from the Revised Cardiac Risk Index): patients with no clinical risk factors may proceed to surgery. Patients with one or two risk factors may proceed to surgery with heart rate control; noninvasive testing may be considered only if it will change management. Patients with three or more clinical risk factors warrant more scrutiny. These patients scheduled for vascular operations should be considered for noninvasive testing—if it will change management. On the other hand, even those with three or more risk factors scheduled for intermediate-risk operations should proceed to surgery with perioperative heart rate control. Noninvasive testing for this group should, again, be considered only if it will change management.

Perioperative β-adrenergic receptor blockade

The issue of the use of β-adrenergic receptor blocking agents in the perioperative period is controversial, largely because of limited and conflicting data from studies performed in the surgical setting, particularly determinations of the ideal target population, type of β-adrenergic receptor blocking agent, route of administration, and duration of preoperative drug titration. Nevertheless, the latest guidelines state that perioperative β-adrenergic receptor blockade is indicated for patients already on β-adrenergic receptor blocking agents for the treatment of angina, hypertension, symptomatic arrhythmias, or congestive heart failure or for patients undergoing vascular operations who are at high cardiac risk because of ischemia (as was shown on preoperative testing).

β-Adrenergic receptor blocking agents are probably recommended for patients with coronary artery disease who are undergoing vascular or intermediate-risk to high-risk operations. They may be considered for any patient undergoing a vascular operation or those at intermediate to high cardiac risk who are undergoing intermediate-risk to high-risk operations. Their usefulness is uncertain in patients undergoing either intermediate-risk procedures or vascular operations with one or no clinical risk factors. Patients with absolute or relative contraindications to the use of β-adrenergic receptor blocking agents—such as decompensated heart failure, nonischemic cardiomyopathy, and severe valvular heart disease in the absence of flow-limiting coronary disease or severe bronchospastic disease—should not receive them. Statins should be continued, however, throughout the perioperative period in all patients.

Patients with prior percutaneous coronary interventions

Nonelective operations in patients who have undergone percutaneous coronary interventions (PCIs), with or without coronary artery stenting, present significant risks in the perioperative period. An increasing number of these patients require noncardiac operations within a year of stenting, and this puts them at high risk of developing stent thrombosis, which is associated with significant morbidity and mortality risks (significantly higher with drug-eluting stents as compared with bare metal stents). The reasons for the perioperative hypercoagulability of these patients is multifactorial and include the prothrombotic state associated with surgery, incomplete stent re-endothelialization, and premature discontinuation of dual-antiplatelet therapy. As per the revised ACC/AHA guidelines, patients who have undergone PCIs without stent placement should have elective operations delayed for at least 2 weeks to allow for healing of vessel injury at the balloon inflation site. Patients who have had bare metal stents implanted should have elective operations delayed for at least 4 to 6 weeks while being on dual-antiplatelet therapy to reduce the incidence of stent thrombosis. Lastly, drug-eluting stents pose a particular challenge due to the highly delayed re-endothelialization that is a hallmark of these stents, markedly increasing the risk of early and late stent thrombosis in patients in whom drug-eluting stents have been placed. The key factor that has been associated with this issue is the premature discontinuation of dual-antiplatelet therapy. For this reason, the guidelines mandate that elective noncardiac operations be delayed for at least 12 months while the patient is on dual-antiplatelet therapy to reduce the risk of catastrophic stent thrombosis occurring, which has a mortality rate ranging from 20% to 45%. For those patients who must undergo operations during the recommended time period for dual-antiplatelet therapy, serious consideration should be given to performing the procedure without interruption of dual-antiplatelet therapy. For certain procedures in which the surgical bleeding risk is unacceptably high with these drugs (neurosurgery, posterior chamber eye surgery, prostate resections), the dual therapy may have to be discontinued preoperatively and restarted as soon as possible in the postoperative period. Alternatively, if acceptable, monotherapy with only aspirin may be continued perioperatively to mitigate thrombotic risk.

Patients with cardiac-rhythm management devices

Patients with cardiac-rhythm management devices (pacemakers and implantable cardioverter-defibrillators [ICDs]) are another group of high-risk patients who need special attention. These patients should have their devices interrogated within 3 to 6 months after undergoing an operation. The risk of device malfunction is high perioperatively owing to electromagnetic interference. Reliance on a magnet is not recommended, except for emergencies. Preoperatively, the pacemaker should be reprogrammed to asynchronous mode. In the case of ICDs, the antitachyarrhythmia function should be turned off by reprogramming or by use of a magnet in an emergency. Postoperatively, the function of the device should be interrogated, especially if an electrosurgical unit has been used, and in the case of ICDs, tachyarrhythmia function must be restored.